Date: 2016-01-21
Type of information: Publication of results in a medical journal
phase: 3
Announcement: publication of results in The New English Journal of Medicine
Company: Allergan (Ireland)
Product: Viberzi® (US)/Truberzii® (UE) (eluxadoline)
Action
mechanism: Eluxadoline is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist that acts locally in the gut. Based on efficacy of Viberzi® 75 mg and 100 mg at 12 weeks of treatment, Viberzi® was approved by the FDA as a twice-daily, oral treatment indicated for use in adults suffering from IBS-D. Viberzi® has mixed opioid receptor activity - it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist
Disease: irritable bowel syndrome with diarrhea (IBS-D)
Therapeutic area: Digestive diseases - Gastrointestinal diseases - Inflammatory diseases
Country:
Trial details:
Latest
news: * On January 21, 2016, Allergan plc (NYSE: AGN) announced today the publication of the positive results of the Phase III trials of Viberzi® (US)/Truberzii® (UE) C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine (NEJM). The trial results are from two Phase III randomized, multi-center, multi-national, double-blind, placebo-controlled trials (Studies 1 and 2).
In these trials, significantly more patients treated with Viberzi® experienced improvements in diarrhea and abdominal pain, as compared with placebo. Efficacy was defined as simultaneous reductions in the daily worst abdominal pain score by >30% as compared to the baseline weekly average and a reduction in the Bristol Stool Scale (BSS) to <5, on at least 50% of the days within a 12-week treatment interval. These trial results demonstrated sustained and effective relief of both symptoms.
A total of 1280 patients in Study 1 and 1145 patients in Study 2 received treatment with Viberzi® 75 mg, Viberzi® 100 mg or placebo twice daily. Overall, the patients were a mean age of 45 years (ranging from 18 to 80 years with 10% at least 65 years of age or older), 66% female, 86% white, 11% black, and 27% Hispanic.
Study 1 and Study 2 included identical 26-week double-blind, placebo-controlled treatment periods. Study 1 continued double-blinded for an additional 26 weeks for long-term safety (total of 52 weeks of treatment). Study 2 included a 4-week single-blinded, placebo-withdrawal period upon completion of the 26-week treatment period. During the double-blind treatment phase and the single-blinded placebo withdrawal phase, patients were allowed to take loperamide rescue medication for the acute treatment of uncontrolled diarrhea, but were not allowed to take any other antidiarrheal, antispasmodic agent or rifaximin for their diarrhea. Additionally, patients were allowed to take aspirin-containing medications or nonsteroidal anti-inflammatory drugs, but no narcotic or opioid containing agents.
